Abstract

BackgroundIschemic stroke patients with active cancer frequently experience early neurological deterioration (END); however, the predictors of END are not well studied. The neutrophil to lymphocyte ratio (NLR) has recently been described as a predictor of poor outcomes in cancer and stroke. However, its role in cancer-related stroke has not been addressed.AimWe aimed to evaluate the association between the NLR and END in cancer-related stroke patients.MethodsWe included 85 cryptogenic stroke patients with active cancer. END was defined as an increase ≥ 4 on the total National Institutes of Health Stroke Scale (NIHSS) score within 72 hours of admission. The NLR was calculated as the ratio of the absolute neutrophil count to the absolute lymphocyte count. We obtained the NLR during the following three periods: at admission, 1–3 days after admission (D 1–3 NLR) and 4–7 days after admission (D 4–7 NLR).ResultsEND occurred in 15 (18%) of the 85 patients. END was significantly associated with the initial NIHSS score, infarction volume, and the D 1–3 NLR. In multivariate analysis, a higher D 1–3 NLR, measured before END events, remained an independent predictor of END [adjusted odds ratio = 2.78, 95% confidence interval = 1.09–7.08, P = 0.032]. In terms of temporal changes in the NLR, the END group showed a tendency toward temporal increase in the NLR at D 1–3 (P = 0.061) with subsequent decrements in the D 4–7 NLR (P = 0.088), while the non-END group showed no significant changes in the NLR between periods.ConclusionsThis study demonstrated that a higher NLR could predict END events in cryptogenic stroke patients with active cancer. However, the results should be confirmed in further large prospective studies.

Highlights

  • Ischemic stroke is common among cancer patients and indicates a poorer prognosis for such patients [1,2]

  • early neurological deterioration (END) was significantly associated with the initial National Institutes of Health Stroke Scale (NIHSS) score, infarction volume, and the D 1–3 neutrophil to lymphocyte ratio (NLR)

  • A higher D 1–3 NLR, measured before END events, remained an independent predictor of END [adjusted odds ratio = 2.78, 95% confidence interval = 1.09–7.08, P = 0.032]

Read more

Summary

Introduction

Ischemic stroke is common among cancer patients and indicates a poorer prognosis for such patients [1,2]. The mechanisms of stroke in this group are more complex, especially when both conventional vascular risk factors and cancer-specific factors related to thrombogenicity are involved [3,4]. Due to these heterogeneous traits, cancer-related stroke may result from different stroke mechanisms and require specific treatments. Despite their clinical importance, studies on cancer-related stroke and its early clinical outcomes have not been well addressed. Neurological deterioration (END) following ischemic stroke is a clinically important event because it is strongly related to a subsequent poor prognosis. Its role in cancer-related stroke has not been addressed

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call